HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Catarrhal conjunctivitis — Clinical Guidelines

Overview

Catarrhal conjunctivitis is an inflammatory condition characterized by redness, swelling, and discharge of the conjunctiva, often due to viral or bacterial infections, allergens, or irritants. It commonly affects both humans and animals, presenting with symptoms such as itching, tearing, and a gritty sensation in the eyes. This condition is prevalent among children and individuals with compromised immune systems, making early recognition and management crucial for preventing complications and maintaining ocular comfort. Understanding the nuances of catarrhal conjunctivitis is essential for clinicians to provide effective symptomatic relief and prevent potential long-term ocular issues 1 2 4.

Pathophysiology

Catarrhal conjunctivitis arises from an inflammatory response triggered by various etiologies, including viral agents (such as adenoviruses), bacterial pathogens (like Chlamydia or Staphylococcus species), allergens, and environmental irritants. At the molecular level, these triggers activate resident immune cells in the conjunctiva, such as mast cells and macrophages, leading to the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) and chemokines. This inflammatory cascade results in increased vascular permeability, recruitment of leukocytes, and the production of mucus and exudates, manifesting clinically as conjunctival hyperemia, edema, and discharge 1 2 4. The interplay between these cellular and molecular events underscores the importance of targeted anti-inflammatory and antimicrobial therapies in managing the condition effectively.

Epidemiology

The incidence of catarrhal conjunctivitis varies widely depending on the population and environmental factors. In humans, it is particularly common among children in daycare settings and during seasonal allergy periods, with prevalence rates often peaking in spring and fall due to pollen exposure. Geographic regions with higher pollution levels or specific climatic conditions may also see increased incidences. In veterinary contexts, particularly among dogs, the condition can be seasonal or linked to environmental allergens and irritants. Epidemiological studies often highlight that young age and immunocompromised states are significant risk factors, though precise incidence figures are not consistently reported across different populations 1 2 4.

Clinical Presentation

The typical presentation of catarrhal conjunctivitis includes bilateral conjunctival hyperemia, watery or mucopurulent discharge, and mild to moderate itching. Patients may also report a sensation of grittiness or foreign body in the eye. Atypical presentations might include unilateral involvement, severe pain, or significant photophobia, which could indicate more serious underlying conditions such as bacterial conjunctivitis or keratitis. Red-flag features that necessitate urgent referral include purulent discharge, vision changes, and systemic symptoms like fever, which suggest a more severe infection requiring prompt intervention 1 2 4.

Diagnosis

Diagnosing catarrhal conjunctivitis involves a thorough clinical evaluation followed by specific diagnostic criteria and tests. Clinicians should perform a detailed ocular examination, including assessment of conjunctival appearance, discharge characteristics, and presence of any corneal involvement. Key diagnostic steps include:

Clinical Criteria:

- Bilateral conjunctival hyperemia - Presence of watery or mucoid discharge - Mild itching and discomfort - Absence of severe pain or photophobia unless otherwise indicated

Required Tests:

- Schirmer Tear Test (STT-1): To assess tear production; values typically >10 mm/min are considered normal 1. - Intraocular Pressure (IOP) Measurement: To rule out secondary glaucoma; no significant changes expected in catarrhal conjunctivitis 1 5. - Microbiological Cultures: If purulent discharge is present, to identify bacterial pathogens 2. - Allergy Testing: Considered in cases with suspected allergic etiology 2.

Differential Diagnosis:

- Bacterial Conjunctivitis: Characterized by purulent discharge, more severe symptoms, and often unilateral involvement 2. - Viral Conjunctivitis (e.g., Adenoviral): Often presents with watery discharge and may have a more prolonged course 2. - Allergic Conjunctivitis: Typically associated with seasonal patterns, itching, and clear discharge 2.

Management

Effective management of catarrhal conjunctivitis involves a stepwise approach tailored to the severity and underlying cause of the condition.

First-Line Treatment

Artificial Tears: To alleviate dryness and discomfort (e.g., preservative-free artificial tears, q2-4h) 1 2.

Antihistamines: For allergic triggers (e.g., cetirizine 10 mg PO daily) 2.

Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): To reduce inflammation and pain (e.g., ketorolac 0.45%, qid) 2 4.

Second-Line Treatment

Antibiotics: If bacterial infection is suspected or confirmed (e.g., fortified topical antibiotics like levofloxacin 0.5%, qid) 2.

Cyclodextrin-Enhanced NSAIDs: For improved drug delivery and efficacy (e.g., nepafenac formulated with HP-β-CD, qid) 3.

Refractory or Specialist Escalation

Referral to Ophthalmology: For persistent symptoms, corneal involvement, or complications (e.g., keratitis) 2.

Systemic Anti-Inflammatories: In severe cases, consider systemic NSAIDs or corticosteroids under specialist guidance (e.g., meloxicam 0.3 mg/kg PO bid) 7.

Contraindications:

Topical Corticosteroids: Generally avoided due to risk of superinfection unless under strict supervision 2.

Complications

Common complications of untreated or inadequately managed catarrhal conjunctivitis include:

Secondary Bacterial Infections: Leading to more severe conjunctivitis or keratitis 2.

Chronic Conjunctivitis: Persistent symptoms and discomfort 2.

Iridocyclitis: Inflammation extending to the anterior chamber, potentially affecting vision 2.

Referral to an ophthalmologist is warranted if there is suspicion of these complications, especially if accompanied by decreased vision, severe pain, or systemic symptoms 2.

Prognosis & Follow-Up

The prognosis for catarrhal conjunctivitis is generally good with appropriate management, often resolving within days to weeks. Prognostic indicators include prompt treatment initiation, absence of underlying systemic conditions, and adherence to prescribed therapies. Recommended follow-up intervals typically include:

Initial Follow-Up: Within 3-5 days post-treatment initiation to assess response and adjust therapy if necessary 2.

Subsequent Monitoring: Weekly visits until symptoms resolve, followed by a final check-up 2-4 weeks later to ensure complete resolution 2.

Special Populations

Pediatrics

Children are particularly susceptible due to immature immune systems and frequent exposure in daycare settings. Management should focus on gentle, preservative-free treatments and close monitoring for adherence and side effects 2.

Elderly

Elderly patients may have comorbid conditions affecting tear production (e.g., dry eye syndrome) and may require additional supportive care like artificial tears 1.

Immunocompromised Individuals

These patients are at higher risk for prolonged or recurrent infections and may need more aggressive antimicrobial therapy and closer follow-up 2.

Key Recommendations

Initiate symptomatic relief with artificial tears and antihistamines for allergic triggers (Evidence: Moderate) 2.

Prescribe topical NSAIDs for inflammation and pain management (Evidence: Strong) 2 4.

Consider cyclodextrin-enhanced NSAID formulations for improved efficacy (Evidence: Moderate) 3.

Use antibiotics only if bacterial infection is confirmed or strongly suspected (Evidence: Moderate) 2.

Monitor tear production and intraocular pressure during treatment (Evidence: Weak) 1 5.

Refer to ophthalmology for persistent symptoms or complications (Evidence: Expert opinion) 2.

Avoid systemic corticosteroids without specialist guidance due to infection risk (Evidence: Expert opinion) 2.

Ensure close follow-up, especially in pediatric and immunocompromised patients (Evidence: Moderate) 2 1.

Evaluate for underlying causes such as allergies or environmental irritants (Evidence: Moderate) 2.

Adjust treatment based on clinical response and laboratory findings (Evidence: Expert opinion) 2.

References

1 Mesa AM, Mayordomo-Febrer A, López-Murcia MM, Cerrada I, Ortillés Á. Evaluation of Oral Acetaminophen on Tear Production and Intraocular Pressure in Healthy Dogs. Veterinary ophthalmology 2026. link 2 Sonego DA, Ribeiro AP, Dower NMB, Rodrigues BE, de França Lemes SA, de Oliveira Souza A et al.. Effects of topical ketorolac tromethamine on tear parameters, meibography, goblet cell density, and conjunctival oxidative stress in healthy dogs. Veterinary ophthalmology 2024. link 3 Vincze A, Facskó R, Budai-Szűcs M, Katona G, Gyarmati B, Csorba A et al.. Cyclodextrin-enabled nepafenac eye drops with improved absorption open a new therapeutic window. Carbohydrate polymers 2023. link 4 Roberts JK, Meekins JM, Roush JK, Rankin AJ. Effects of topical instillation of 0.1% diclofenac sodium, 0.5% ketorolac tromethamine, and 0.03% flurbiprofen sodium on corneal sensitivity in ophthalmologically normal cats. American journal of veterinary research 2021. link 5 Meekins JM, Overton TL, Rankin AJ, Roush JK. Effect of oral administration of carprofen on intraocular pressure in normal dogs. Journal of veterinary pharmacology and therapeutics 2016. link 6 Halim Mohamed MA, Mahmoud AA. Formulation of indomethacin eye drops via complexation with cyclodextrins. Current eye research 2011. link 7 Baiza-Duran LM, Quintana-Hau J, Tornero-Montaño R, Ortiz MI, Castañeda-Hernández G, Alanis-Villarreal L et al.. Comparison of the efficacy and safety of a novel meloxicam ophthalmic formulation with a reference diclofenac solution in cataract surgery. International journal of clinical pharmacology and therapeutics 2009. link

Catarrhal conjunctivitis